학술논문
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.
Document Type
Article
Author
Buckstein, Rena; Chodirker, Lisa; Yee, Karen W.L.; Geddes, Michelle; Leitch, Heather A.; Christou, Grace; Banerji, Versha; Leber, Brian; Khalaf, Dina; St-Hilaire, Eve; Finn, Nicholas; Nevill, Thomas; Keating, Mary-Margaret; Storring, John; Parmentier, Anne; Thambipillai, Aksharh; Tang, Derek; Westcott, Christopher; Cameron, Chris; Spin, Paul
Source
Subject
*RED blood cell transfusion
*BLOOD transfusion
*MYELODYSPLASTIC syndromes
*BLOOD transfusion reaction
*ERYTHROCYTES
*PATIENT reported outcome measures
*
*
*
*
*
Language
ISSN
1042-8194
Abstract
Many patients with lower-risk myelodysplastic syndromes (LR MDS) require long-term red blood cell (RBC) transfusions to manage anemia. The consequences of RBC transfusions in LR MDS with ring sideroblasts (LR MDS-RS) are not well known. We estimated the association between cumulative RBC dose density and clinical and patient-reported outcomes using data from the MDS-CAN registry for patients enrolled between January 2008 and December 2018. Outcomes included overall survival, hospitalization, and health-related quality of life (HRQoL). A total of 145 enrolled patients with LR MDS and RS ≥5% had a median follow-up time of 27.1 months; 45 had no transfusions during follow-up, 51 had <1 transfusion per month, and 49 had ≥1 transfusion per month. The cumulative density of RBC transfusions was associated with significantly greater mortality, hospitalization, and inferior HRQoL, suggesting that exposure to RBC transfusion may constitute a significant treatment burden in patients with LR MDS-RS. [ABSTRACT FROM AUTHOR]